T1	Treatment 0 8	Afatinib
T2	Treatment 16 28	methotrexate
T3	Treatment 448 456	Afatinib
T4	Treatment 596 604	afatinib
T5	Treatment 619 631	methotrexate
T6	Treatment 1316 1397	EGFR-targeted antibody therapy (but not EGFR-targeted tyrosine-kinase inhibitors)
T7	Treatment 1476 1551	oral afatinib (40 mg/day) or intravenous methotrexate (40 mg/m(2) per week)
T8	Treatment 2344 2352	afatinib
T9	Treatment 2364 2377	methotrexate.
T10	Treatment 2475 2487	the afatinib
T11	Treatment 2502 2518	the methotrexate
T12	Treatment 3046 3057	in 44 (14%)
T13	Treatment 3087 3102	and 18 (11%) of
T14	Treatment 3134 3148	INTERPRETATION
